KURA ONCOLOGY INC (KURA) Fundamental Analysis & Valuation

NASDAQ:KURA • US50127T1097

Current stock price

8.77 USD
-0.06 (-0.68%)
At close:
8.83 USD
+0.06 (+0.68%)
After Hours:

This KURA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. KURA Profitability Analysis

1.1 Basic Checks

  • KURA had negative earnings in the past year.
  • In the past year KURA has reported a negative cash flow from operations.
  • In the past 5 years KURA always reported negative net income.
  • KURA had negative operating cash flow in 4 of the past 5 years.
KURA Yearly Net Income VS EBIT VS OCF VS FCFKURA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M -200M -300M

1.2 Ratios

  • KURA has a Return On Assets (-37.74%) which is comparable to the rest of the industry.
  • KURA has a worse Return On Equity (-160.03%) than 66.47% of its industry peers.
Industry RankSector Rank
ROA -37.74%
ROE -160.03%
ROIC N/A
ROA(3y)-31.54%
ROA(5y)-29.76%
ROE(3y)-80.17%
ROE(5y)-59.72%
ROIC(3y)N/A
ROIC(5y)N/A
KURA Yearly ROA, ROE, ROICKURA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • With an excellent Gross Margin value of 99.92%, KURA belongs to the best of the industry, outperforming 99.03% of the companies in the same industry.
  • The Profit Margin and Operating Margin are not available for KURA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KURA Yearly Profit, Operating, Gross MarginsKURA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. KURA Health Analysis

2.1 Basic Checks

  • KURA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for KURA has been increased compared to 1 year ago.
  • The number of shares outstanding for KURA has been increased compared to 5 years ago.
  • The debt/assets ratio for KURA is higher compared to a year ago.
KURA Yearly Shares OutstandingKURA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
KURA Yearly Total Debt VS Total AssetsKURA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of -1.70, we must say that KURA is in the distress zone and has some risk of bankruptcy.
  • KURA has a Altman-Z score (-1.70) which is in line with its industry peers.
  • A Debt/Equity ratio of 0.06 indicates that KURA is not too dependend on debt financing.
  • KURA has a worse Debt to Equity ratio (0.06) than 60.08% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z -1.7
ROIC/WACCN/A
WACC9.52%
KURA Yearly LT Debt VS Equity VS FCFKURA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • KURA has a Current Ratio of 6.06. This indicates that KURA is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 6.06, KURA is doing good in the industry, outperforming 62.40% of the companies in the same industry.
  • KURA has a Quick Ratio of 6.05. This indicates that KURA is financially healthy and has no problem in meeting its short term obligations.
  • KURA has a better Quick ratio (6.05) than 62.79% of its industry peers.
Industry RankSector Rank
Current Ratio 6.06
Quick Ratio 6.05
KURA Yearly Current Assets VS Current LiabilitesKURA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. KURA Growth Analysis

3.1 Past

  • The earnings per share for KURA have decreased strongly by -56.65% in the last year.
  • KURA shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.24%.
EPS 1Y (TTM)-56.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-318.18%
Revenue 1Y (TTM)25.24%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-67.83%

3.2 Future

  • KURA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.69% yearly.
  • KURA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 57.64% yearly.
EPS Next Y-22.01%
EPS Next 2Y4.43%
EPS Next 3Y9.92%
EPS Next 5Y26.69%
Revenue Next Year-28.22%
Revenue Next 2Y21.71%
Revenue Next 3Y26.46%
Revenue Next 5Y57.64%

3.3 Evolution

KURA Yearly Revenue VS EstimatesKURA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
KURA Yearly EPS VS EstimatesKURA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. KURA Valuation Analysis

4.1 Price/Earnings Ratio

  • KURA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year KURA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KURA Price Earnings VS Forward Price EarningsKURA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KURA Per share dataKURA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.43%
EPS Next 3Y9.92%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. KURA Dividend Analysis

5.1 Amount

  • No dividends for KURA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KURA Fundamentals: All Metrics, Ratios and Statistics

KURA ONCOLOGY INC

NASDAQ:KURA (5/1/2026, 8:00:03 PM)

After market: 8.83 +0.06 (+0.68%)

8.77

-0.06 (-0.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength54.04
Industry Growth13.66
Earnings (Last)04-30
Earnings (Next)08-05
Inst Owners97.05%
Inst Owner Change-0.8%
Ins Owners2.36%
Ins Owner Change9.14%
Market Cap778.43M
Revenue(TTM)67.48M
Net Income(TTM)-278.67M
Analysts82.86
Price Target31.79 (262.49%)
Short Float %17.27%
Short Ratio9.88
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-41.92%
Min EPS beat(2)-86.01%
Max EPS beat(2)2.17%
EPS beat(4)1
Avg EPS beat(4)-52.41%
Min EPS beat(4)-86.01%
Max EPS beat(4)2.17%
EPS beat(8)4
Avg EPS beat(8)-17.42%
EPS beat(12)8
Avg EPS beat(12)-9.28%
EPS beat(16)12
Avg EPS beat(16)-4.98%
Revenue beat(2)0
Avg Revenue beat(2)-64.04%
Min Revenue beat(2)-77.38%
Max Revenue beat(2)-50.69%
Revenue beat(4)1
Avg Revenue beat(4)-43.97%
Min Revenue beat(4)-77.38%
Max Revenue beat(4)11.33%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.97%
PT rev (3m)-4.24%
EPS NQ rev (1m)31.47%
EPS NQ rev (3m)-199.85%
EPS NY rev (1m)-20.63%
EPS NY rev (3m)-38.49%
Revenue NQ rev (1m)2.19%
Revenue NQ rev (3m)-78.59%
Revenue NY rev (1m)1.95%
Revenue NY rev (3m)-51.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.54
P/FCF N/A
P/OCF N/A
P/B 4.47
P/tB 4.47
EV/EBITDA N/A
EPS(TTM)-3.18
EYN/A
EPS(NY)-3.88
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS0.76
BVpS1.96
TBVpS1.96
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -37.74%
ROE -160.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.92%
FCFM N/A
ROA(3y)-31.54%
ROA(5y)-29.76%
ROE(3y)-80.17%
ROE(5y)-59.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 643.22%
Cap/Sales 9.84%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.06
Quick Ratio 6.05
Altman-Z -1.7
F-Score2
WACC9.52%
ROIC/WACCN/A
Cap/Depr(3y)239.56%
Cap/Depr(5y)201.38%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-56.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-318.18%
EPS Next Y-22.01%
EPS Next 2Y4.43%
EPS Next 3Y9.92%
EPS Next 5Y26.69%
Revenue 1Y (TTM)25.24%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-67.83%
Revenue Next Year-28.22%
Revenue Next 2Y21.71%
Revenue Next 3Y26.46%
Revenue Next 5Y57.64%
EBIT growth 1Y-57.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-40.05%
EBIT Next 3Y1.15%
EBIT Next 5Y3.76%
FCF growth 1Y-152.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-147.69%
OCF growth 3YN/A
OCF growth 5YN/A

KURA ONCOLOGY INC / KURA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of KURA ONCOLOGY INC (KURA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to KURA.


What is the valuation status of KURA ONCOLOGY INC (KURA) stock?

ChartMill assigns a valuation rating of 0 / 10 to KURA ONCOLOGY INC (KURA). This can be considered as Overvalued.


What is the profitability of KURA stock?

KURA ONCOLOGY INC (KURA) has a profitability rating of 1 / 10.


What is the expected EPS growth for KURA ONCOLOGY INC (KURA) stock?

The Earnings per Share (EPS) of KURA ONCOLOGY INC (KURA) is expected to decline by -22.01% in the next year.